A high frequency and a significantly inferior survival of RUNX1 co‐mutations in patients with AML or MDS carrying ASXL1mt was observed in previous studies, both in the elderly cohort39, 40 and the younger cohort.23 This evidence concerns the gene RUNX1 and myelodysplastic syndrome.